Antisense Pharma GmbH – Product Pipeline Review – 2012 - Global Market Direct's pharmaceuticals report, "Antisense Therapeutics Limited - Product Pipeline Review - 2012" provides data on the Antisense Therapeutics Limited's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from our proprietary databases, Antisense Therapeutics Limited's corporate website, SEC filings, investor presentations and featured press releases, both from Antisense Therapeutics Limited and industry-specific third party sources, put together by our team.
Scope
- Antisense Therapeutics Limited - Brief Antisense Therapeutics Limited overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Antisense Therapeutics Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Antisense Therapeutics Limited with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Antisense Therapeutics Limited's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Antisense Therapeutics Limited's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Antisense Therapeutics Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Antisense Therapeutics Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Antisense Therapeutics Limited.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Antisense Therapeutics Limited and identify potential opportunities in those areas.
Table of Contents
Table of Contents
List of Tables
List of Figures
Antisense Pharma GmbH Snapshot
Antisense Pharma GmbH Overview
Key Information
Key Facts
Antisense Pharma GmbH – Research and Development Overview
Key Therapeutic Areas
Antisense Pharma GmbH – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Antisense Pharma GmbH – Pipeline Products Glance
Antisense Pharma GmbH – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Antisense Pharma GmbH Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Antisense Pharma GmbH – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Antisense Pharma GmbH – Drug Profiles
NCE For Neoplasms
Product Description
Mechanism of Action
R&D Progress
trabedersen
Product Description
Mechanism of Action
R&D Progress
Antisense Pharma GmbH – Pipeline Analysis
Antisense Pharma GmbH – Pipeline Products by Therapeutic Class
Antisense Pharma GmbH – Pipeline Products by Route of Administration
Antisense Pharma GmbH – Pipeline Products By Mechanism of Action
Antisense Pharma GmbH – Recent Pipeline Updates
Antisense Pharma GmbH - Dormant Projects
Antisense Pharma GmbH - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
trabedersen
Antisense Pharma GmbH – Locations And Subsidiaries
Head Office
Antisense Pharma GmbH, Recent Developments
Antisense Pharma GmbH- Press Release
Jul 24, 2012: Antisense Pharma Receives FDA Orphan Drug Designation For Trabedersen To Treat Malignant Melanoma
Jun 04, 2012: Antisense Pharma Presents Trabedersen Phase I/II Complete Data At ASCO Annual Meeting
Feb 29, 2012: Antisense Pharma Terminates Phase III High Grade Glioma Trial And Expands First-Line Treatment With Trabedersen
Jan 11, 2012: Antisense Pharma To Pursue First-Line Treatment With Trabedersen, Terminates 2nd Line Phase III High Grade Glioma Trial
Apr 27, 2009: Antisense Pharma Begins Pivotal Phase III Clinical Trial With Trabedersen In Aggressive Brain Tumors
Financial Deals Landscape
Antisense Pharma GmbH, Deals Summary
Antisense Pharma GmbH, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Antisense Pharma Raises $11.58 Million In Venture Financing
Antisense Pharma Raises $18 Million In Series E Financing
Antisense Pharma Raises $38 Million In Venture Financing
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Antisense Pharma GmbH, Key Information
Antisense Pharma GmbH, Key Facts
Antisense Pharma GmbH – Pipeline by Indication, 2012
Antisense Pharma GmbH – Pipeline by Stage of Development, 2012
Antisense Pharma GmbH – Monotherapy Products in Pipeline, 2012
Antisense Pharma GmbH – Phase III, 2012
Antisense Pharma GmbH – Phase I, 2012
Antisense Pharma GmbH – Pre-Clinical, 2012
Antisense Pharma GmbH – Discovery, 2012
Antisense Pharma GmbH – Pipeline By Therapeutic Class, 2012
Antisense Pharma GmbH – Pipeline By Route of Administration, 2012
Antisense Pharma GmbH – Pipeline Products By Mechanism of Action, 2012
Antisense Pharma GmbH – Recent Pipeline Updates, 2012
Antisense Pharma GmbH - Dormant Developmental Projects,2012
Antisense Pharma GmbH - Discontinued Pipeline Products, 2012
Antisense Pharma GmbH, Deals Summary
Antisense Pharma Raises $11.58 Million In Venture Financing
Antisense Pharma Raises $18 Million In Series E Financing
Antisense Pharma Raises $38 Million In Venture Financing
List of Figures
Antisense Pharma GmbH – Pipeline by Indication, 2012
Antisense Pharma GmbH – Pipeline by Stage of Development, 2012
Antisense Pharma GmbH – Monotherapy Products in Pipeline, 2012
Antisense Pharma GmbH – Pipeline By Therapeutic Class, 2012
Antisense Pharma GmbH – Pipeline By Route of Administration, 2012 18